CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($) |
3 Months Ended | 6 Months Ended | ||
---|---|---|---|---|
Oct. 31, 2024 |
Oct. 31, 2023 |
Oct. 31, 2024 |
Oct. 31, 2023 |
|
Income Statement [Abstract] | ||||
Revenue | $ 0 | $ 0 | $ 0 | $ 0 |
Operating expenses: | ||||
Research and development costs | 97,470 | 82,033 | 193,486 | 186,516 |
Compensation expense | 283,333 | 229,159 | 672,817 | 469,157 |
Director fees | 138,000 | 306,738 | 276,000 | 356,953 |
Legal and professional | 469,685 | 519,073 | 980,241 | 844,301 |
General and administrative | 117,572 | 272,517 | 252,403 | 1,627,919 |
Total operating expenses | 1,106,060 | 1,409,520 | 2,374,947 | 3,484,846 |
Loss from operations | (1,106,060) | (1,409,520) | (2,374,947) | (3,484,846) |
Other income (expenses): | ||||
Interest income | 382,562 | 894,181 | 929,994 | 1,770,059 |
Change in fair value of warrant liability | 1,829,000 | 4,075,000 | 3,913,000 | 2,623,000 |
Change in fair value of derivative liability | 980,000 | (769,000) | 2,184,000 | (1,299,000) |
Change in fair value of convertible note receivable | 435,000 | 0 | 680,000 | 0 |
Change in fair value of warrant asset - Femasys | 276,000 | 0 | (1,234,000) | 0 |
Change in fair value of investment - TNF | (4,265,000) | 0 | (3,540,734) | 0 |
Gain on related party investment - TNF | 0 | 0 | 21,395,734 | 0 |
Other expense | (1,062) | (765) | (1,252) | (2,614) |
Total other income, net | (363,500) | 4,199,416 | 24,326,742 | 3,091,445 |
Net income (loss) | (1,469,560) | 2,789,896 | 21,951,795 | (393,401) |
Preferred stock dividends | (443,958) | (586,886) | (1,129,759) | (906,735) |
Preferred stock accretion | (1,045,357) | (4,461,097) | (3,193,404) | (7,733,130) |
Net income (loss) attributable to common stockholders | $ (2,958,875) | $ (2,258,087) | $ 17,628,632 | $ (9,033,266) |
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash, stock and payment-in-kind (PIK). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Amount of interest income earned from interest bearing assets classified as other. No definition available.
|
X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Noninterest expense related to directors' fees which are fees paid by an Entity to its directors. Directors' fees may be paid in addition to salary and other benefits. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense. No definition available.
|
X | ||||||||||
- References No definition available.
|
X | ||||||||||
- Definition The net result for the period of deducting operating expenses from operating revenues. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition The amount of accretion of the preferred stock redemption discount during the period. No definition available.
|
X | ||||||||||
- Definition A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
X | ||||||||||
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|